Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,138 public posts
Filter results
Impact of progression at baseline ... on-treatment progression ...
"There is a discussion about the optimal timing to initiate or switch treatment in metastatic
castration
-resistant prostate cancer (mCRPC).
"There is a discussion about the optimal timing to initiate or switch treatment in metastatic
castration
-resistant prostate cancer (mCRPC).
pjoshea13
in
Advanced Prostate Cancer
5 years ago
STOMP - Oligometastatic PCa.
Immediate treatment also delayed the time to development of
castration
-resistant prostate cancer (CRPC). Overall survival (OS) rate was 80-90% in both groups.
Immediate treatment also delayed the time to development of
castration
-resistant prostate cancer (CRPC). Overall survival (OS) rate was 80-90% in both groups.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Ratio of periprostatic to subcutaneous fat thickness on MRI is an independent survival predictor in hormone-naïve men with advanced PCa
This could be useful for predicting which patients are more likely to develop
castration
-resistant PCa.
This could be useful for predicting which patients are more likely to develop
castration
-resistant PCa.
pjoshea13
in
Advanced Prostate Cancer
5 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
FDA Grants Priority Review to Olaparib for HRR-Mutant mCRPC - Targeted Oncology - January 20, 2020
[i]The FDA has granted a Priority Review to the New Drug Application for olaparib (Lynparza) as treatment for patients with metastatic
castration
-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations, who have
[i]The FDA has granted a Priority Review to the New Drug Application for olaparib (Lynparza) as treatment for patients with metastatic
castration
-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations, who have
cujoe
in
Fight Prostate Cancer
4 years ago
Radium-223 treatment in CRPC & presence of Primary Tumor.
[Epub ahead of print] Radium-223 treatment in
castration
resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
[Epub ahead of print] Radium-223 treatment in
castration
resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
pjoshea13
in
Advanced Prostate Cancer
5 years ago
A difficult customer
The whole concept of chemical
castration
, which is what ADT is, seems bizarre to me. It's also based on research from the dawn of endocrinology so is more than 70 years old.
The whole concept of chemical
castration
, which is what ADT is, seems bizarre to me. It's also based on research from the dawn of endocrinology so is more than 70 years old.
Notewell
in
Advanced Prostate Cancer
5 years ago
Onvansertib Helps Overcome Resistance to Zytiga in mCRPC Patients, Interim Phase 2 Data Show
An article from Prostate Cancer Today Trovagene’s investigational oral therapy onvansertib may help overcome resistance to Zytiga (abiraterone acetate) in men with metastatic
castration
-resistant prostate cancer (mCRPC), updated Phase 2 data continue to suggest.
An article from Prostate Cancer Today Trovagene’s investigational oral therapy onvansertib may help overcome resistance to Zytiga (abiraterone acetate) in men with metastatic
castration
-resistant prostate cancer (mCRPC), updated Phase 2 data continue to suggest.
Philly13
in
Advanced Prostate Cancer
5 years ago
Salvage lymph node dissection in nonmetastatic castration-resistant PCA.
[u]Conclusion[/u]: "In patients with nonmetastatic,
castration
-resistant prostate cancer, sLND resulted in greater PSA decrease than ADT.
[u]Conclusion[/u]: "In patients with nonmetastatic,
castration
-resistant prostate cancer, sLND resulted in greater PSA decrease than ADT.
pjoshea13
in
Advanced Prostate Cancer
5 years ago
Pseudoprogression.
[Epub ahead of print] Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic
Castration
-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
[Epub ahead of print] Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic
Castration
-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
pjoshea13
in
Advanced Prostate Cancer
5 years ago
Retreatment With Radium-223 in Patients With Castration-Resistant Prostate Cancer and Bone Metastases
TAKE-HOME MESSAGE •Radium-223 is approved for patients with
castration
-resistant prostate cancer and symptomatic bone metastases. Repeat treatment after initial therapy has not been studied.
TAKE-HOME MESSAGE •Radium-223 is approved for patients with
castration
-resistant prostate cancer and symptomatic bone metastases. Repeat treatment after initial therapy has not been studied.
Balsam01
in
Advanced Prostate Cancer
5 years ago
Zytiga vs xtandi
211 patients with metastatic
castration
-resistant prostate cancer (mCRPC) treated with abiraterone acetate or enzalutamide.
211 patients with metastatic
castration
-resistant prostate cancer (mCRPC) treated with abiraterone acetate or enzalutamide.
Magnus1964
in
Advanced Prostate Cancer
5 years ago
SM-88 Report; #2 of 2 from Tyme
in prostate cancer patients with rising prostate-specific antigen (PSA): More than 450,000 of these patient cases annually in the U.S. alone SM-88 therapy did not exhibit typical side effects associated with hormonal
castration
from androgen-deprivation therapy (ADT) At 6 months, 100% of patients
in prostate cancer patients with rising prostate-specific antigen (PSA): More than 450,000 of these patient cases annually in the U.S. alone SM-88 therapy did not exhibit typical side effects associated with hormonal
castration
from androgen-deprivation therapy (ADT) At 6 months, 100% of patients
mistersafety
in
Advanced Prostate Cancer
5 years ago
Radium-223 Treatment in Castration-Resistant Bone Metastatic Prostate Cancer
Urologic Oncology: Seminars & Original Investigations Radium-223 Treatment in
Castration
-Resistant Bone Metastatic Prostate Cancer. Should Be the Primary Tumor Always Treated? Urol.
Urologic Oncology: Seminars & Original Investigations Radium-223 Treatment in
Castration
-Resistant Bone Metastatic Prostate Cancer. Should Be the Primary Tumor Always Treated? Urol.
Balsam01
in
Advanced Prostate Cancer
5 years ago
Impact of Abiraterone Acetate Plus Prednisone or Enzalutamide on Patient-Reported Outcomes in Patients With Metastatic Castration-Resistant
TAKE-HOME MESSAGE •AQUARiUS (NCT02813408) was a prospective, 12-month, European observational study including 211 patients with metastatic
castration
-resistant prostate cancer (mCRPC) treated with abiraterone acetate or enzalutamide.
TAKE-HOME MESSAGE •AQUARiUS (NCT02813408) was a prospective, 12-month, European observational study including 211 patients with metastatic
castration
-resistant prostate cancer (mCRPC) treated with abiraterone acetate or enzalutamide.
Balsam01
in
Advanced Prostate Cancer
5 years ago
2019 Top Stories in Advanced Prostate Cancer: Cabazitaxel vs Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic
Castration
-Resistant Prostate Cancer-PROSELICA. J Clin Oncol. 2017;35(28):3198-3206.
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic
Castration
-Resistant Prostate Cancer-PROSELICA. J Clin Oncol. 2017;35(28):3198-3206.
Balsam01
in
Advanced Prostate Cancer
5 years ago
Radium-223 Treatment in Castration-Resistant Bone Metastatic Prostate Cancer
Small sample study, favoring RP: "TAKE-HOME MESSAGE Radium-223 (223Ra) is indicated for patients with bony metastatic castrate-resistant prostate cancer. It is not known whether treatment of the primary tumor confers benefit. In this study, the authors reviewed outcomes in patients receiving 223Ra on
Small sample study, favoring RP: "TAKE-HOME MESSAGE Radium-223 (223Ra) is indicated for patients with bony metastatic castrate-resistant prostate cancer. It is not known whether treatment of the primary tumor confers benefit. In this study, the authors reviewed outcomes in patients receiving 223Ra on
snoraste
in
Advanced Prostate Cancer
5 years ago
Improved Survival With Apalutamide in Castration-Resistant Prostate Cancer
Annals of Oncology Apalutamide and Overall Survival in Non-Metastatic
Castration
-Resistant Prostate Cancer Ann.
Annals of Oncology Apalutamide and Overall Survival in Non-Metastatic
Castration
-Resistant Prostate Cancer Ann.
Balsam01
in
Advanced Prostate Cancer
5 years ago
PSA time to nadir as a prognostic factor of first-line docetaxel treatment in CRPC
Abstract OBJECTIVE: Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic
castration
-resistant prostate cancer (mCRPC) in China.
Abstract OBJECTIVE: Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic
castration
-resistant prostate cancer (mCRPC) in China.
pjoshea13
in
Advanced Prostate Cancer
5 years ago
Docetaxel vs Surveillance After Radical Radiotherapy for Intermediate- or High-Risk Prostate Cancer
This suggests that, in patients with early, low-burden disease who benefit from temporary
castration
therapy, chemotherapy does not “wipe out” early
castration
-resistant clones or add significantly to the hormonal therapy benefits.
This suggests that, in patients with early, low-burden disease who benefit from temporary
castration
therapy, chemotherapy does not “wipe out” early
castration
-resistant clones or add significantly to the hormonal therapy benefits.
Balsam01
in
Advanced Prostate Cancer
5 years ago
Indirect Comparisons of Efficacy Between Combination Approaches in Metastatic Hormone-Sensitive Prostate Cancer
– Gautam Jayram, MD Urology Written by Fred Saad MD, FRCS For over 70 years, androgen deprivation therapy (ADT) has been the standard of care for metastatic
castration
-sensitive prostate cancer (mCSPC).
– Gautam Jayram, MD Urology Written by Fred Saad MD, FRCS For over 70 years, androgen deprivation therapy (ADT) has been the standard of care for metastatic
castration
-sensitive prostate cancer (mCSPC).
Balsam01
in
Advanced Prostate Cancer
5 years ago
1
...
35
36
37
...
57
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1015 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest